ACADIA Pharmaceuticals Inc (ACAD)
17.07
-0.12
(-0.70%)
USD |
NASDAQ |
Mar 28, 16:00
16.99
-0.08
(-0.47%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.847B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -7.68% |
| Valuation | |
| PE Ratio | 12.55 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.968 |
| Price to Book Value | 3.885 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 77.18% |
Profile
Edit
| Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc. |
| URL | https://www.acadia.com |
| Investor Relations URL | https://ir.acadia.com |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 08, 2025 (est.) |
| Last Earnings Release | Feb. 26, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc. |
| URL | https://www.acadia.com |
| Investor Relations URL | https://ir.acadia.com |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 08, 2025 (est.) |
| Last Earnings Release | Feb. 26, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |